Лучшие больницы для «Atrial Septal Defect (ASD) Treatment» в Дубай, ОАЭ

The total cost of ASD treatment in India typically ranges from USD 3,500 to USD 8,000, making it one of the most cost-competitive destinations globally for congenital heart procedures. This range covers transcatheter device closure (Amplatzer or equivalent occluder) at the lower end (USD 3,500–5,500) and open or minimally invasive surgical repair under cardiopulmonary bypass at the higher end (USD 5,500–8,000), inclusive of surgeon fees, anesthesia, ICU and ward stay, and pre-discharge echocardiography at NABH- and JCI-accredited hospitals. In the UAE (Dubai and Abu Dhabi), the equivalent costs range from approximately USD 9,000 to USD 18,000, reflecting higher facility overhead, premium hospital infrastructure, and the cost of living in the Emirates. Transcatheter closure in the UAE typically costs USD 9,000–12,000, while open surgical repair ranges from USD 13,000–18,000 at JCI- and DHA-licensed centers including Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai, and American Hospital Dubai. Both destinations offer substantially lower pricing than comparable procedures in the United States (USD 40,000–80,000) or the United Kingdom (GBP 25,000–45,000 privately), without compromise in outcomes, technology, or specialist expertise. GAF Healthcare provides transparent, itemized cost estimates prior to travel so patients can make fully informed financial decisions.

The required in-country recovery period before international air travel depends on the type of ASD intervention performed. Patients who undergo transcatheter device closure (e.g., Amplatzer Septal Occluder) are typically advised to remain in-country for a minimum of 2–3 weeks following the procedure. This period allows for a follow-up echocardiogram at Day 7–10 to confirm device stability and position, clinical cardiology review, and sufficient early endothelialization of the device to reduce the risk of thrombus formation during the prolonged immobility of a long-haul flight. Most transcatheter patients are cleared to fly between 2 and 3 weeks post-procedure, subject to their cardiologist's written fit-to-fly assessment. Patients who undergo open or minimally invasive surgical repair under cardiopulmonary bypass require a longer recovery period of 4–6 weeks in-country. This timeline accommodates wound healing (sternal or thoracotomy incision), resolution of post-pericardiotomy syndrome if it occurs, physiotherapy milestones, and a comprehensive pre-departure echocardiogram and clinical review. The formal fit-to-fly letter is issued by the treating cardiologist only after the final review confirms hemodynamic stability, satisfactory wound healing, and no active effusion or arrhythmia. Patients undertaking long-haul flights are advised to wear graduated compression stockings, maintain adequate hydration, and ambulate in the aircraft cabin every 60–90 minutes to minimize the risk of deep vein thrombosis. GAF Healthcare coordinates all follow-up appointments and ensures the fit-to-fly clearance documentation is ready before the patient's departure.

ASD treatment performed at high-volume congenital cardiology centers in India and the UAE achieves complete defect closure rates of 95–98% at one year, as confirmed by post-procedural color-flow Doppler echocardiography. For transcatheter device closure — the preferred approach for suitable secundum ASDs — the procedural success rate (defined as device deployment without major adverse events and with no or trivial residual shunt immediately post-procedure) exceeds 96% in experienced centers, with long-term closure rates of 97–98% at five-year follow-up. Small residual shunts detected immediately post-procedure in approximately 5–10% of cases resolve spontaneously within 6–12 months as the device endothelializes. For surgical repair — either primary suture closure or pericardial patch repair — complete and durable closure is achieved in over 99% of cases at experienced centers, with a very low incidence of significant residual defect requiring re-intervention. Physiological outcomes following successful ASD closure are excellent: most patients experience normalization of right ventricular dimensions within 6–12 months, significant improvement in exercise tolerance and functional class, reduction in pulmonary arterial pressure toward normal in those without fixed pulmonary vascular disease, and a return to a near-normal life expectancy. The best outcomes are achieved when closure is performed before the development of irreversible pulmonary arterial hypertension or significant right ventricular dysfunction, underscoring the importance of timely intervention. Patients treated in adulthood may retain some degree of right atrial remodeling and a slightly elevated risk of atrial fibrillation even after successful closure; however, the risk of progressive cardiac deterioration is substantially curtailed. GAF Healthcare pre-screens all partner hospitals based on published procedural volumes, complication registries, and specialist credentials to ensure patients are treated at centers where these benchmark outcomes are consistently achieved.